- Trials with a EudraCT protocol (366)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
366 result(s) found for: Vaccine therapy.
Displaying page 1 of 19.
EudraCT Number: 2021-001993-52 | Sponsor Protocol Number: IMCOVAS | Start Date*: 2021-05-20 |
Sponsor Name:University of Antwerp | ||
Full Title: Assessment of the immunogenicity and safety of marketed vaccines for COVID-19 after regular schedule and adapted vaccine schedules and routes: BNT162b2 (Comirnaty®; Pfizer-BioNTech), mRNA-1273 Vacc... | ||
Medical condition: Coronavirus disease-19 (COVID-19) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2009-013837-92 | Sponsor Protocol Number: 113459 | Start Date*: 2010-09-04 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A phase III, open, randomized, trial to evaluate the immunogenicity and safety of a single or two-dose schedule of the A/California/7/2009 (H1N1)v-like candidate vaccine manufactured in Dresden adj... | ||
Medical condition: Immunization against A/California/7/2009 (H1N1)v-like influenza in male and female subjects aged 18 years and above. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-015008-25 | Sponsor Protocol Number: 113630 | Start Date*: 2009-09-08 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A phase III, open, non-randomized, trial to evaluate the immunogenicity and safety of a two-dose schedule of the A/California/7/2009 (H1N1)v-like candidate vaccine manufactured in Dresden adjuvante... | ||
Medical condition: Immunization against A/California/7/2009 (H1N1)v-like influenza in male and female subjects aged 18 years and above. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-002014-14 | Sponsor Protocol Number: COV-PBO-MO28 | Start Date*: 2021-04-20 |
Sponsor Name:Fakultní nemocnice Hradec Králové | ||
Full Title: Antibody and cellular response 28 days after the first dose of COVID-19 vaccine (Moderna) and then 33 weeks after the second dose and 8-12 weeks after the third dose in clinically stable patients w... | ||
Medical condition: Antibody and cellular response 28 days after the first dose of COVID-19 vaccine (Moderna) and then 33 weeks after the second dose and 8-12 weeks after the third dose in clinically stable patients w... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-000930-32 | Sponsor Protocol Number: SJ2021005 | Start Date*: 2021-04-27 |
Sponsor Name:AZ Sint-Jan Brugge-Oostende AV | ||
Full Title: COVID-19: Documentation of humoral and cellular immune response of hemodialysis patients after vaccination against SARS-CoV-2 | ||
Medical condition: hemodialysis patients hemodialysis patients with comorbidities | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2009-014449-96 | Sponsor Protocol Number: 113574 | Start Date*: 2009-08-10 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A phase II, observer-blind, randomized trial to evaluate the safety and immunogenicity of a two-dose schedule of the A/California/7/2009 (H1N1)v-like candidate vaccine manufactured in Dresden adjuv... | ||
Medical condition: Immunization against A/California/7/2009 (H1N1)v-like influenza in male and female subjects aged 18 years and above. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-002691-39 | Sponsor Protocol Number: APHP200039 | Start Date*: 2022-04-27 | |||||||||||
Sponsor Name:Assistance Publique-Hôpitaux de Paris | |||||||||||||
Full Title: INTERVENTIONAL RESEARCH PROTOCOL INVOLVING HUMAN PARTICIPANTS CONCERNING A MEDICINAL PRODUCT FOR HUMAN USE | |||||||||||||
Medical condition: Obese adult patients with BMI ≥35 kg/m2 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-001924-31 | Sponsor Protocol Number: STH18166 | Start Date*: 2014-08-26 | |||||||||||
Sponsor Name:Sheffield Teaching Hospitals NHS Foundation Trust | |||||||||||||
Full Title: Exploring novel mechanisms of vaccine failure and induction of pulmonary immunity following live attenuated influenza vaccination in HIV infected and uninfected individuals: a pilot study. | |||||||||||||
Medical condition: HIV (effect of HIV on the response to live attenuated intranasal influenza vaccine) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-014448-13 | Sponsor Protocol Number: 113572 | Start Date*: 2009-09-02 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A phase III, randomised, single-blind study to evaluate the immunogenicity and safety of sequential administration of a licensed seasonal trivalent vaccine and the pandemic H1N1 influenza candidate... | ||
Medical condition: Immunization against A/California/7/2009 (H1N1)v-like influenza in male and female subjects aged 61 years or above. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-016078-33 | Sponsor Protocol Number: 113866 | Start Date*: 2009-10-06 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A phase III, observer-blind, randomised trial to evaluate the safety and immunogenicity of a two-dose schedule of the A/California/7/2009 (H1N1)v-like candidate vaccine manufactured in Dresden adju... | ||
Medical condition: Immunisation against A/California/7/2009 (H1N1)v-like influenza in male and female subjects aged 18 to 60 years. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-013931-39 | Sponsor Protocol Number: 113525 | Start Date*: 2009-09-08 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A phase II, observer-blind, randomized study to assess the immunogenicity, safety and reactogenicity of a two-dose schedule with GSK Biologicals’ A/California/7/2009 (H1N1)v-like vaccine containing... | ||
Medical condition: Immunization against A/California/7/2009 (H1N1)v-like influenza and seasonal influenza (2009-2010) in male and female subjects aged 61 years and older. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-000228-33 | Sponsor Protocol Number: CE/17-12-06 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:CHU Saint-Pierre | |||||||||||||
Full Title: Prospective longitudinal study on immunogenicity, induction of cellular immune responses and safety of vaccination against HPV with the 9valent vaccine in HIV-positive women | |||||||||||||
Medical condition: Immune responses to administration of 9valent vaccine against HPV in HIV-positive women | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Female | ||||||||||||
Trial protocol: BE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-004558-44 | Sponsor Protocol Number: 2021-00604 | Start Date*: 2021-10-10 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:UMCG | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: Optimal Booster Strategy for SARS-CoV-2 Vaccination in Kidney Transplant patients | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: COVID-19 is associated with severely increased morbidity and mortality in kidney transplant patients. Available data show that the immune response after a standard regimen of two mRNA vaccinations ... | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: NL (Completed) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2021-002693-10 | Sponsor Protocol Number: VAC3_SARS-CoV2_seroconversion_study | Start Date*: 2021-07-15 |
Sponsor Name:Medical University of Vienna, Department for Internal Medicine III, Division of Rheumatology | ||
Full Title: A Phase II Study to Evaluate Safety and Efficacy to a Third Vaccination in Immunocompromised Patients with Inadequate Humoral Response after Primary mRNA SARS-CoV-2 (Covid-19) Vaccination | ||
Medical condition: Vaccination against SARS-CoV-2 in patients with immunosuppressive therapy or immunodeficiencies | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-000120-19 | Sponsor Protocol Number: HN1901 | Start Date*: 2020-05-05 |
Sponsor Name:Cliniques universitaires Saint-Luc | ||
Full Title: Activity and safety of peptide-based immunotherapy in an umbrella window pre-operative opportunity phase II study in patients with squamous cell carcinoma of the head and neck. | ||
Medical condition: Head and neck cancer elective for surgery | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2021-004608-17 | Sponsor Protocol Number: SJ2021100 | Start Date*: 2021-10-18 |
Sponsor Name:AZ Sint-Jan Brugge-Oostende AV | ||
Full Title: Effectivity of a mRNA-1273 booster vaccine against Covid-19 breakthrough infections in hemodialysis patients: a multicenter interventional study | ||
Medical condition: hemodialysis patients | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2009-014419-11 | Sponsor Protocol Number: 113535 | Start Date*: 2009-10-07 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A phase III, observer-blind, randomized, study in adults aged between 18 and 60 years to assess the immunological equivalence of the Quebec-manufactured A/California/7/2009 (H1N1)v-like antigen adj... | ||
Medical condition: Immunization against A/California/7/2009 (H1N1)v-like influenza in male and female subjects aged 18 to 60 years. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: FR (Completed) DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-013710-27 | Sponsor Protocol Number: 113456 | Start Date*: 2009-09-04 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A phase III, observer-blind, randomized trial to evaluate the safety and immunogenicity of a two-dose schedule of the A/California/7/2009 (H1N1)v-like candidate vaccine manufactured in Dresden adju... | ||
Medical condition: Immunization against A/California/7/2009 (H1N1)v-like influenza in male and female subjects aged 18 to 60 years. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-001485-26 | Sponsor Protocol Number: 102248,111274 | Start Date*: 2015-06-22 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A phase III, double-blind, randomised, placebo-controlled, multi-center study to assess the efficacy, safety and immunogenicity of two or three doses of GSK Biologicals’ oral live attenuated human ... | ||
Medical condition: Healthy volunteers | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2009-012642-22 | Sponsor Protocol Number: 0887x1-20003 | Start Date*: 2009-12-18 |
Sponsor Name:Swedish CLL-group | ||
Full Title: A Randomized Phase III Trial to Determine Whether Conjugated Pneumococcal Vaccine Can Improve the Immune Responsiveness Compared to Polyclonal Pneumococcal Vaccine in Patients With Untreated Chroni... | ||
Medical condition: The purpose of the study is to determine wheter patients with chronic lymphocytic leukaemia (CLL) will benefit from vaccination with conjugated pneumococcal vaccine compared to conventional 23-vale... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
• EEA CTAs: Date study was authorised to proceed
• Outside EU/EEA: Date study was submitted in EudraCT
• Outside EU/EEA: Date study was submitted in EudraCT
